Ambrx and MabSpace Biosciences to Collaborate on Novel Antibody Drug Conjugates

Friday, January 06, 2017

San Diego based Ambrx Inc. and Suzhou based MabSpace Biosciences have agreed to collaborate on discovery and development of multiple novel ADCs in China and around the world for oncology.

According to the agreement, MabSpace will employ its proprietary immune tolerance breaking technology to generate and identify humanized antibodies suitable for ADC development, and Ambrx will employ its EuCode based site-specific conjugation technology to develop lead ADC molecules. The parties will jointly develop and share the cost and rights of the resulting ADC products.

“We are pleased to collaborate with MabSpace to discover and develop novel ADCs,” Dr. Alex Qiao, CEO of Ambrx, Inc. said. “This collaboration can potentially enhance our site specific protein conjugation technology platform capabilities.”

“MabSpace is honored to work with a prestigious company like Ambrx who has extensive capabilities in ADC discovery and development,” said Dr. Xueming Qian, Chairman and CEO of MabSpace Biosciences. “MabSpace’s unique immune tolerance breaking-based antibody discovery platform and its ability to obtain antibodies with diverse epitopes is well suited for the development of ADC and therapeutic applications. The collaboration with Ambrx is our third deal with established biopharma companies for antibody based therapeutics development with our immune tolerance breaking technology.”

TOP